Association Study with 77 SNPs Confirms the Robust Role for the rs10830963/G of MTNR1B Variant and Identifies Two Novel Associations in Gestational Diabetes Mellitus Development

Klara Rosta; Zahra Al-Aissa; Orsolya Hadarits; Jürgen Harreiter; Ákos Nádasdi; Fanni Kelemen; Dagmar Bancher-Todesca; Zsolt Komlósi; László Németh; János Rigó Jr.; István Sziller; Anikó Somogyi; Alexandra Kautzky-Willer; Gábor Firneisz

doi:10.1371/journal.pone.0169781

Abstract

Context

Genetic variation in human maternal DNA contributes to the susceptibility for development of gestational diabetes mellitus (GDM).

Objective

We assessed 77 maternal single nucleotide gene polymorphisms (SNPs) for associations with GDM or plasma glucose levels at OGTT in pregnancy.

Methods

960 pregnant women (after dropouts 820: case/control: m99’WHO: 303/517, IADPSG: 287/533) were enrolled in two countries into this case-control study. After genomic DNA isolation the 820 samples were collected in a GDM biobank and assessed using KASP (LGC Genomics) genotyping assay. Logistic regression risk models were used to calculate ORs according to IADPSG/m’99WHO criteria based on standard OGTT values.

Results

The most important risk alleles associated with GDM were rs10830963/G of MTNR1B (OR = 1.84/1.64 [IADPSG/m’99WHO], p = 0.0007/0.006), rs7754840/C (OR = 1.51/NS, p = 0.016) of CDKAL1 and rs1799884/T (OR = 1.4/1.56, p = 0.04/0.006) of GCK. The rs13266634/T (SLC30A8, OR = 0.74/0.71, p = 0.05/0.02) and rs7578326/G (LOC646736/IRS1, OR = 0.62/0.60, p = 0.001/0.006) variants were associated with lower risk to develop GDM. Carrying a minor allele of rs10830963 (MTNR1B); rs7903146 (TCF7L2); rs1799884 (GCK) SNPs were associated with increased plasma glucose levels at routine OGTT.

Conclusions

We confirmed the robust association of MTNR1B rs10830963/G variant with GDM binary and glycemic traits in this Caucasian case-control study. As novel associations we report the minor, G allele of the rs7578326 SNP in the LOC646736/IRS1 region as a significant and the rs13266634/T SNP (SLC30A8) as a suggestive protective variant against GDM development. Genetic susceptibility appears to be more preponderant in individuals who meet both the modified 99’WHO and the IADPSG GDM diagnostic criteria.

Citation: Rosta K, Al-Aissa Z, Hadarits O, Harreiter J, Nádasdi Á, Kelemen F, et al. (2017) Association Study with 77 SNPs Confirms the Robust Role for the rs10830963/G of MTNR1B Variant and Identifies Two Novel Associations in Gestational Diabetes Mellitus Development. PLoS ONE 12(1): e0169781. https://doi.org/10.1371/journal.pone.0169781

Editor: Yvonne Böttcher, University of Oslo, NORWAY

Received: August 1, 2016; Accepted: December 21, 2016; Published: January 10, 2017

Copyright: © 2017 Rosta et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the European Foundation for the Study of Diabetes (EFSD): New Horizons Collaborative Research Initiative (http://www.europeandiabetesfoundation.org/index.php/ct-menu-item-9/14-sample-data-articles/168-efsd-new-horizons-collaborative-research-initiative). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Abnormal glucose tolerance first recognized during pregnancy is defined as gestational diabetes mellitus (GDM). The estimated prevalence of GDM varies according to the study population and diagnostic criteria. A plethora of different GDM classification methods and diagnostic guidelines are available [1]. Prevalence estimates of gestational diabetes mellitus indicate that it is a common disease in developed countries with a prevalence ranging from 8.1–14.8% in Hungary (HUN) [2] and >10% in Austria (AT) [1], depending on the diagnostic criteria applied.

Pregnancy is generally characterized by increased adiposity and increased insulin resistance. Insulin resistance during pregnancy occurs partially due to the increased production of human placental lactogen, estrogen and prolactin especially in the second and third trimesters and also due to weight gain. Individuals with limited beta cell response to compensate for physiologically increased insulin resistance are more prone to develop GDM.

Due to the trends in modern societies the more prevalent clinical risk factors, such as higher pre-pregnancy body mass index (BMI) [3] and advanced age [4] at pregnancy resulted in increased insulin- resistance and a need for a compensatory increase in beta cell response. In line with this the prevalence of GDM started to increase sharply in the early 90s [4].

The role for genetic factors in disease development is confirmed by findings that women with a diabetic sibling have an 8.4-fold increased risk of GDM [5]. Since beta cell dysfunction is known to play a critical role in GDM [6, 7] recent evidence from a twin study demonstrating a 75% heritability in insulin secretion variability in younger adults [8] underlines the importance of genetic components in the development of GDM.

As GDM and type 2 diabetes mellitus (T2D) share similarities in their pathogenesis with respect to impaired insulin secretion and increased insulin resistance, research efforts focused on mapping their genetic properties. These studies demonstrated that GDM and T2D share common genetic background, with similar magnitude of effect sizes on the same risk alleles [9]. A few authors even suggested that GDM and type 2 diabetes are two aspects of the same entity [10]

Despite the number of genome wide associations studies (GWAS) performed and reports on associations for selected genotypes in GDM, the protective and risk genetic loci of GDM are still not fully elucidated [9, 11–17]. This might be due to differences in the study populations (ethnicity), small sample size and the different diagnostic criteria used. Most of the GWAS studies in this disease were conducted in Asian populations [11], highlighting the need for confirmation in Caucasian populations [18].

In our study, we aimed to identify maternal gene variants that are associated with GDM or influence fasting and 2-hour glucose levels after a routine 75 g oral glucose tolerance test (OGTT) during pregnancy (24-28^th gestational week [gw]). A set of 77 gene variants single nucleotide polymorphisms (SNPs) were selected and the majority of these variants were common variants previously reported to be associated with either T2D, GDM or with important metabolic traits, such as hemoglobin A1c levels, fasting and 2 hour plasma glucose levels, insulin-resistance indices, proinsulin levels or with other related traits such as the BMI [19]. We compared the impact of two different diagnostic criteria of GDM on the association of gene variants with GDM. In Austria, we used the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria [GDM: 75gCH OGTT at 24–28 gw: fasting plasma glucose (FPG)≥5.1mmol/L, 60 min plasma glucose (PG)≥10.0 mmol/L, 120 min PG≥8.5 mmol/L], while the Hungarian centers used the modified 1999 World Health Organization (WHO) recommendation [GDM: 75gCH OGTT at 24–28 gw: FPG≥6.1 mmol/L, 120 min PG≥7.8 mmol/L].

We assessed T2D susceptibility gene variants to confirm the interrelated genetic background of GDM in a Caucasian population. We also hypothesized, that patient selection by different diagnostic criteria in GDM might influence the results of the genetic association study, as different threshold values in OGTT can have an influence on patient distribution between the control (CNTRL) and GDM group and thus could represent a bias if remains without adjustment.

Our results support the conception of a similar genetic background to GDM and T2D, however there are variances in the effect sizes of the risk/protective SNPs in between the two diseases. We confirmed the robust role of rs10830963/G of Melatonin receptor 1B (MTNR1B) gene variant in developing GDM or glycemic traits. Furthermore, we identified two novel associations, namely the minor, G allele of the rs7578326 SNP in the LOC646736/IRS1 region as a significant, and the rs13266634/T SNP Solute carrier family 30 member 8 (SLC30A8) as a suggestive protective variant against GDM development. According to our findings, the minor allele frequency of the known common causal MTNR1B variant, rs10830963 is significantly higher in the GDM subgroup which meet both the modified 99’ WHO and the IADPSG diagnostic criteria.

Materials and Methods

Patients

The institutional (Semmelweis University, Regional and Institutional Committee of Science and Research Ethics and Ethics Committee of the Medical University of Vienna) and the national ethical bodies of Hungary (Medical Research Council Scientific and Research Committee) and Austria (Federal Office for Safety and Health care) have approved the study, which was conducted according to the declaration of Helsinki. Pregnant women were enrolled to the study after signing the informed consent for the whole project and a special consent for storing their samples in a biobank for use in anonymized genetic studies.

Patients were recruited from two Hungarian and a single Austrian centers in the framework of the European Foundation for the Study of Diabetes New Horizons initiative.

Inclusion criteria

The diagnosis of GDM (inclusion criteria) has been established according to the national recommendations of the two countries: the Austrian study center applied the IADPSG criteria [GDM: 75gCH OGTT at 24–28 gw: FPG≥5.1mmol/L, 60 min PG≥10.0 mmol/L, 120 min PG≥8.5 mmol/L], while the Hungarian centers used the modified 1999 WHO recommendation [GDM: 75gCH OGTT at 24–28 gw: FPG≥6.1 mmol/L, 120 min PG≥7.8 mmol/L] [20, 21].

Exclusion criteria

Exclusion criteria were based in part on the STrengthening the Reporting of observational (case-control) studies in Epidemiology statement for Genetic Association studies (STREGA) guidelines [22]. In addition we excluded patients with: diabetes in pregnancy (i.e. overt diabetes)and diabetes categories other than GDM (e.g.: autoimmune), any apparent major disease or chronically treated with medication with known impact on glycemic control, in vitro fertilization, missing major clinical data, twin pregnancies or variables likely to be associated with population stratification (e.g.: non-European ancestry).

Clinical data collection

We collected all relevant clinical information that was used in the case- control study or qualitative trait assessments, including the result of the OGTT, pre-pregnancy BMI, maternal age and the birth-weight percentiles [23].

Research design

As two different diagnostic GDM criteria were applied (IADPSG or the modified 99' WHO) in the two participating countries the following protocol was employed for the analysis of genotype associations: we first had to reclassify the entire dataset of the whole study population according to both criteria based on the OGTT results (FPG and 2 hour PG values) as a ‘diagnosis stratification procedure’. This was possible since there was no medical intervention prior to the 75g OGTT and the test itself was performed in the standardized time-frame of gestation (24^th-28^th gestational week). Those individuals in whom the GDM diagnosis was established exclusively on the basis of the 60 min OGTT result remained in the GDM group in the ‘diagnosis stratification procedure’. Such cases are rare (less than 5.7% according to the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) Study [24] and 13% in the participating Austrian study population). We have performed all binary analysis twice, first using the 99’ modified WHO criteria and second using the IADPSG criteria.

A set of 77 SNPs were selected based on the results of prior genome wide association studies (GWAS) on T2D, BMI, Insulin resistance (IR), Insulin secretion/ beta cell function, plasma glucose or serum insulin level traits. Functionally, the reported genes were suggested to be implicated in the incretin effect, beta-cell function or genesis, potassium channel function, amyloid formation, zinc transport, insulin resistance, obesity development, insulin-like growth factor (IGF) system, vessel formation, glucose homeostasis, circadian rhythm, neuronal regulation of appetite, energy balance or immunoregulation (S1 Table).

Subsequently we provided two numerically different odds ratios and p-values for each gene variants that were significantly associated with GDM according to the corresponding diagnostic system applied in the analysis.

Genomic DNA isolation and genotyping

Genomic DNA was isolated using a magnetic bead based robotized approach (Hamilton Robotics, Magna Starlet, Bonaduz, Switzerland) from EDTA-anticoagulated whole blood samples obtained from cubital veins. Kompetitive Allele Specific PCR (KASP^™) genotyping (FRET [fluorescence resonant energy transfer] based assay) (LGC Genomics, Teddington, Middlesex, UK) was used for the bi-allelic discrimination of 77 SNPs. The overall call rate for all SNPs assessed exceeded the 97% and no discordant genotypes were identified in the control samples of which genomic DNA were isolated in two different runs and subsequently genotyped separately in duplicates for all SNPs. Results were presented using the SNP viewer software (version 1.99, Hoddesdon, UK) and genotype data were extracted for statistical analysis.

Statistical analysis

GDM as binary trait.

All statistical analyses of this case-control study were carried out in a specially designed program in R-project language. We first analyzed associations between genotypes according to the 77 assessed SNPs and the diagnosis of gestational diabetes mellitus as a case-control study. As the diagnosis of GDM was originally established according to criteria (IADPSG or modified 99' WHO) which was used in the center of the patient care provider, we first had to reclassify the entire dataset of the whole study population according to both criteria based on the OGTT results (FPG and 2 hour PG values) as a ‘diagnosis stratification procedure’. Subsequently, we analyzed the data using the logistic regression method under both the dominant and the additive genetic models. We calculated odds ratio (OR), statistical power and p-value for every SNP and used the Benjamini-Hochberg p-correction method to minimize false discovery. ORs were reflective for the Effect Sizes in our case-control study for binary outcomes and were calculated to represent the effects of carrying the reported minor alleles under the dominant model or the effect of the minor allele under the additive genetic model (S2 Table). Subsequently minor allele frequencies were also calculated for each 77 SNPs assessed (S3 Table).

We adjusted our result to the maternal age and pre-pregnancy BMI (S2 Table, Panel A) as covariates in both models, provided that there were no published prior data or direct result in this analysis for the association between the assessed SNPs and pre-pregnancy BMI. If an association between the SNP assessed and pre-pregnancy BMI was observed then only age was used as covariate in adjustment calculations.

Due to that an effect through the causative chain still can be a potential risk for disease development and that BMI-adjustment might possibly be important even if there is a significant SNP-BMI association we reported the p-values and ORs for each 77 SNPs association with GDM one adjusted for age (S2 Table, Panel B) and additionally adjusted for age and pre-pregnancy BMI also (S2 Table, Panel A). However the literature suggests to use the adjusted data by age and BMI as these are often neglected confounders and concludes that this approach results in a more accurate analysis compared to the direct use of unadjusted raw data [18]. Therefore—after exclusion of the causative chain for our most significant findings—we indicate these genetic association results adjusted by age and BMI. Deviations from the Hardy-Weinberg equilibrium in the genotype distributions were assessed for all SNPs using Chi Squared test (S4 Table). We used post-hoc analysis for power calculation. From the p value and statistical power we calculated the exact probability of the existing effect for each gene variant associated significantly with GDM.

Glycemic traits.

In addition we performed analysis for the associations between genotypes according to 77 assessed SNPs and glycemic traits, such as the fasting and 2 hour plasma glucose levels at OGTT and pre-pregnancy BMI using linear regression both under the additive and also under the dominant genetic models. Coefficient values were calculated for significantly associated SNPs in the glycemic trait analysis representing effect sizes both on the fasting and the 2-hour plasma glucose levels and expressed in mmol/L.

To further improve the applied statistics we also re-analyzed our data using a bootstrap resampling method for the linear regression to confirm results when the glycemic traits were analyzed. The bootstrap application was used due to that it is a statistically appropriate way to control and check the stability of the results.

All data were assessed according to the guidelines of STREGA which is an extension of the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement [22].

Clinical characteristics.

Both the Shapiro—Wilks and the Kolmogorov—Smirnov tests were used to assess normality. Mann—Whitney U-test (MWU) was used to compare means and detect differences in case of nonparametric distributions, and 2-tailed t-test with independent variables was used when the distribution was normal. For this re-classified analysis of clinical data we have used Welch-test for comparisons between the countries as the standard deviation (SD) values were not known (and distributions of these parameters are usually asymptotic normal in literature). The, U‘ test was performed with two-sided counterhypothesis due to that we did not hypothesize difference between the two countries.

Results

Altogether 960 pregnant women were enrolled to the study. Dropouts due to insufficient sampling and withdrawn consent eventually reduced the final sample size to 820. Out of the 820, 303 would be diagnosed with GDM according to the 99’ modified WHO criteria and 287 according to the IADPSG criteria. The clinical characteristics of the pregnant population studied are indicated in Table 1.

Download:

Table 1. Clinical characteristics of the pregnant population studied.

https://doi.org/10.1371/journal.pone.0169781.t001

The clinical data (0 min and 120 min plasma glucose values at 75g OGTT, pre-pregnancy BMI, age) were also reclassified according both the IADPSG and m99‘ WHO criteria for the entire (joint Austrian and Hungarian) study population (S5 Table).

In addition to the differences in the plasma glucose values at OGTT significant differences were detected in pre-pregnancy BMI and age at delivery between the GDM and control populations in both countries. We also found differences in the 0’ PG values (HUN>AT, 4.52mM vs. 4.38mM, p<0.05), weight gain during pregnancy in the controls (HUN>AT 13.80kg vs. 9.47kg, p<0.05) and in the 0’ PG (AT>HUN 5.14mM vs. 4.96mM, p<0.05) and 120’ PG (HUN>AT 8.72mM vs.7.38mM, p<0.05) values and age at delivery (HUN>AT 33.7 years vs. 32.04 years, p< 0.05) between the GDM groups of the two countries. However differences in the clinical characteristics between Austria and Hungary are unlikely to affect the genetic study as the clinical characteristics were compared using the country designated diagnosis as grouping variable, in contrast to the genetic analysis, when we regrouped the study population based on the 75g OGTT results according to both GDM diagnostic criteria.

Associations found at significant or suggestive levels in the case-control analysis are indicated in Table 2. There was no significant deviation from the Hardy-Weinberg equilibrium (S4 Table) in the genotype distributions of SNPs with significant results.

Download:

Table 2. Association between maternal gene variants and gestational diabetes mellitus (GDM) using both the International Association of Diabetes and Pregnancy Study Group (IADPSG) and the modified 99' World Health Organization (WHO) GDM diagnostic criteria.

https://doi.org/10.1371/journal.pone.0169781.t002

GDM as binary trait

Association of MTNR1B rs10830963 with GDM.

The most significant findings were related to the rs10830963 polymorphism of the melatonin receptor 1B (MTNR1B): carrying a G allele of the rs10830963 polymorphism of the MTNR1B significantly increased the risk of developing GDM (Table 2) in our case-control study.

The associations of rs10830963 with GDM binary trait resulted in better significance (IADPSG / m99'WHO p: 7x10^-4/6x10^-3) and higher odds ratios (ORs: 1.84/1.64) under the dominant model compared to the additive model (p: 0.003/0.012, OR: 1.48/1.39, respectively) after adjustment to maternal age and pre-pregnancy BMI covariates. This association remained significant under the dominant model, when adjusted p-values were further corrected using the Benjamini-Hochberg (B-H) method. Accordingly, minor allele frequencies (MAF) were higher in the GDM groups than in the control groups under each diagnostic criteria applied (IADPSG: 36% vs. 28%, m99’WHO: 36% vs. 28%; GDM vs. Control groups respectively, Table 2).

Carrying the G risk allele of the MTNR1B rs10830963 in any form was associated with substantially higher odds of disease development in the group of patients who could meet both the m99’ WHO and the IADPSG criteria (OR: 2.05, p<10⁻⁴, z statistic: 4.17) than in those who could be diagnosed with GDM according to only one of the two criteria (Fig 1).

Download:

Fig 1. MTNR1B rs10830963 (true causal gene variant, risk allele G) associated odds ratios of developing GDM by different diagnostic criteria.

https://doi.org/10.1371/journal.pone.0169781.g001

Odds ratios were calculated under the dominant model. Higher OR values indicate the significance of genetic predisposition in those pregnant women who meet both m99’WHO/ IADPSG GDM diagnostic criteria compared to all the other participating pregnant individuals.

CDKAL1 rs7754840 and GCK rs799884 risk polymorphisms in GDM.

Significant associations were found with the intron variant (rs7754840) of the CDK5 regulatory subunit associated protein 1 like 1 (CDKAL1) gene and with the rs1799884 intron variant of the Glucokinase (GCK) gene after adjustment to maternal age and pre-pregnancy BMI covariates under the dominant model (OR rs7754840 IADPSG: 1.51, p = 0.016 and OR rs1799884 IADPSG / m99’WHO 1.4 / 1.56, p = 0.04/0.006). Results (ORs, MAFs and adjusted p-values) according to the different diagnostic criteria are indicated in Table 2.

Protective polymorphisms, including a novel association signal with GDM.

The minor alleles of two common gene variants reduced the risk of developing GDM. A protective common polymorphism was identified as the rs7578326 SNP in the LOC646736/IRS1 region (OR for G allele [IADPSG/m99’ WHO]: 0.62/0,60, p = 0.001/0.006) under the dominant model and adjusting to age and pre-pregnancy BMI. Carrying a T allele of rs13266634 C/T of the SLC30A8 gene significantly reduced the risk of developing GDM under both diagnostic criteria under the additive model (OR [IADPSG/m99’ WHO]: 0.74/0.71, p = 0.05/0.02) (Table 2).

A causative chain (when the association is not significant after age and BMI adjustments only after age adjustment and the SNP associated effect on GDM develops via BMI) might potentially be existing for a few gene variants (HNF1 homeobox B—HNF1B [TCF2] -rs4430796, -rs7501939, clock circadian regulator—CLOCK -rs6832769,—“S2 Table”), however it needs confirmation with larger sample sizes and we may not yet report these associations as clinically meaningful causative chains due to the diminutive p-value differences after the two adjustments.

Association between MTNR1B, GCK, TCF7L2, SLC30A8, LOC646736/IRS1 gene variants and glycemic traits

Fasting plasma glucose levels.

MTNR1B rs10830963 was the most significantly associated SNP with the fasting plasma glucose levels (FPG) (mean effect size: 0.21 mmol/L increase, p<5x10^-4). The A allele of the rs1799884 polymorphism of the GCK gene was also significantly associated with increased FPG levels (mean effect size 0.13mmol/L increase, p = 0.025). All effect sizes are reported in Table 3 after adjustment to pre-pregnancy BMI and age covariates.

Download:

Table 3. Association of common gene variants with fasting and 120 minute plasma glucose values at oral glucose tolerance test (OGTT) in pregnant population.

https://doi.org/10.1371/journal.pone.0169781.t003

Two hour plasma glucose levels at OGTT.

The MTNR1B rs10830963 was the most significantly associated SNP with the 2 hour PG levels (mean effect size 0.605 mmol/L increase, p = 5x10^-4) after adjustments to pre-pregnancy BMI and age covariates and this remained significant even when the adjusted p-value was further corrected to reduce FDR using the Benjamini-Hochberg method (p = 0.044). In addition we found an association between the rs7903146 polymorphism of the transcription factor 7-like 2 (TCF7L2) gene and 2 hour PG values (mean effect size per T allele 0.25mmol/L increase, p = 0.027) after adjustment for pre-pregnancy BMI and age. The rs7578326 SNP in the LOC646736/IRS1 region was associated with decreased (effect size: -0.45 mmol/L, p = 0.0025) 2 hour plasma glucose levels, such as the rs13266634 of the SLC30A8 gene (effect size per T allele: -0.26mmol/L, p = 0.02) (Table 3).

Pre-pregnancy body mass index

All assessed SNPs of the Melanocortin 4 receptor (MC4R, rs10871777, rs571312, rs17782313) were associated with higher pre-pregnancy BMI values at significant level after adjustment to age and using the Benjamini-Hochberg FDR correction method. The LDL receptor related protein 1B (LRP1B, rs2890652), Potassium voltage-gated channel subfamily J member 11 (KCNJ11, rs5219), CDK5 regulatory subunit associated protein 1 like 1 (CDKAL1, rs7754840) and Fat mass and obesity (FTO, rs11642841) gene polymorphisms were associated with pre-pregnancy BMI at suggestive levels (Table 4).

Download:

Table 4. Association of common gene variants with pre-pregnancy body mass index.

https://doi.org/10.1371/journal.pone.0169781.t004

Discussion

We conducted a case-control genetic association study in a Caucasian population with 77 gene variants that were either earlier reported to be associated with the GDM or with T2D due to that GDM and T2D share similar genetic susceptibility background [18]. In addition a few other gene variants (SNPs) with potential contribution to an important metabolic condition were also assessed to detect associations with GDM or other related traits.

We found that the MTNR1B rs10830963/G allele had the most robust association with GDM and also with glycemic traits, including both the FPG and the post-challenge (2 h) PG values at 75g OGTT.

In a recent meta-analysis on GDM genetics the authors concluded that pooled OR for the MTNR1B rs10830963 risk variant was lower in Asians (1.23) compared to Caucasians (1.49). Authors found that only in studies which included subjects with mean pre-pregnancy BMI higher than 25 kg/m², but not with lower mean pre-pregnancy BMI values the MTNR1B rs10830963 risk variant was significantly associated with GDM [18]. Furthermore, in a recent study with early intervention (diet, lifestyle intervention from the 13^th gw) applied in high GDM risk individuals (BMI>30kg/m²) only non-carriers of the risk allele G benefited from the 3 months intervention assessed by PG values at routine OGTT suggesting that MTNR1B rs10830963 variant could modify the efficacy of lifestyle interventions [35]. We found that the rs10830963 MTNR1B gene variant is characterized with ORs between 1.84 and 1.64 (dominant model), depending on the diagnostic criteria (IADPSG / m99’WHO) applied. Corroborating reports of higher OR values for rs10830963/G MTNR1B found in Caucasians compared to Asians are in accordance with these higher OR values we report here due to that our case cohort was with a mean pre pregnancy BMI higher than 25kg/m² (both in Austria and Hungary) [9, 11, 14, 15, 17, 36, 37].

Accordingly, although several studies found that the rs10830963 MTNR1B variant was not associated or only in subgroups associated with fasting and 2 hour glycemic traits, we consistently found associations both with the fasting and post-challenge values with mean 0.21 and 0.61 mmol/L increases in PG levels at OGTT under the dominant model, respectively [11, 12, 14, 15].

Functionally it is important that the MTNR1B rs10830963 risk G allele is predicted to create a recognition motif that matches the consensus sequences of neuronal differentiation 1 (NEUROD1) and other transcription factors. This was suggested to be consistent with that the risk G allele promotes islet MTNR1B expression [38] and the risk G allele also increases FOXA2-bound enhancer activity in islet- and liver-derived cells.

The MTNR1B rs10830963 intron gene variant seems to be a credible causal gene variant which is the driving association signal in contrast to other candidate SNPs (i.e. rs10830962) that may be retrospectively interpreted as lead gene variants [11, 38].

MTNR1B gene encodes one of two high affinity forms of a receptor for melatonin, a pineal gland hormone that regulates glucose metabolism by affecting circadian insulin secretion. MTNR1B variants were associated with FPG values [25] and defective MTNR1B G-protein-coupled receptor signaling on human beta cells decreased glucose sensitivity and impaired insulin secretion [39]. The rs10830963 was associated with impaired first-phase insulin secretion and decreased Homeostasis Model Assessment—Beta (HOMA-B) even in GDM populations [9, 40].

In a GWAS performed using over 2 million (imputed) initial gene variants Korean authors reported the rs7754840 variant of CDKAL1 and also the rs10830963 variant of MTNR1B as risk polymorphisms in GDM [11]. In our study on a Caucasian population however, CDKAL1 rs7754840 gene variant was only associated with GDM at a suggestive level. In contrast, the minor, G allele of the rs7578326 SNP in the LOC646736/IRS1 region is first reported here to decrease the risk to develop GDM and to be associated with decreased fasting and 2 hour plasma glucose levels. This protective effect of the minor, G allele is in concordance with prior reports that identified the major, A allele as the risk allele for T2D in a large-scale association analysis [27]. The IRS1 gene is localized over 500kb downstream of the LOC646736 genomic region harboring the rs7578326 SNP and the genomic distance of linkage is typically less than 200kb. The LOC646736 locus and its relation to insulin resistance was characterized and authors suggested clear genotype effects on insulin signaling in skeletal muscle, however did not argue for causality of IRS1. Additional pathology might be possible, either via the translation of LOC646736 transcripts, however due to the lack of putative protein expression identification in human tissues, it is possible that LOC646736 transcripts are linc (long intergenic non-coding) RNAs that alter insulin signal transduction by either cis or trans regulation [41]. These mechanisms may potentially explain the protective effect of the (minor, G) variant of the rs7578326 in the LOC646736 region we first describe in association with GDM development and also with glycemic traits during pregnancy.

The other protective minor (T) variant identified in this analysis, the rs13266634 (C/T) affects the amino acid residue 325 at the C-terminal of the zinc transporter 8 (ZnT8, SLC30A8), which influences zinc homeostasis. In line with prior [11] reports in Asian population our findings confirm the role of this SLC30A8 variant in Caucasian populations in GDM development. Susceptibility likely evolves via the altered regulation of zinc homeostasis and related changes in insulin production and beta cell function.

The other associations we found with glycemic traits such as the common rs1799884 promoter variant of GCK (with increased FPG levels) and the rs7903146 variant of the TCF7L2 gene (with increased post-challenge PG levels) were reported in prior GDM genetic studies [13, 42, 43].

Regarding the overall architecture of genetic susceptibility of GDM, it should be recognized that many of the gene variants we report here (MTNR1B, CDKAL1, SLC30A8, TCF7L2 and potentially exerts similar effect) were reported to be associated with a reduced first phase insulin secretion, while the second-phase insulin secretion remained intact [34, 44–47]. In contrast to the above set of gene variants the rs7578326 SNP in the LOC646736/IRS 1 region clearly affected insulin sensitivity in previous studies [28, 41].

This genetic architecture of GDM predisposition might be especially relevant nowadays, when clinical risk factors, such as higher pre-pregnancy BMI and age [3, 4] at pregnancy become more prevalent resulting in increased insulin resistance and a need for a compensatory increase in beta cell response and the latter might be substantially limited in genetically susceptible individuals.

According to our findings (Fig 1) the most robust association of the causal MTNR1B variant rs10830963, is more preponderant in those pregnant individuals who meet both the modified 99’ WHO and the IADPSG diagnostic criteria. In contrast it appears to have a more limited role in determining the odds of disease development in those who could be diagnosed as GDM only according to one of the above diagnostic recommendations, but not by the other. This observation, the “clustering of genetic risk” might points towards precision medicine. Individuals with a susceptible genetic background at risk for developing GDM could potentially benefit from earlier diagnosis and treatment than the currently applied general routine testing (OGTT between the 24-28th gestational week). On the other hand, those who might be diagnosed only according to one of the diagnostic recommendations, the role of lifestyle modifications, age at delivery and related epigenetics may be more substantial factors in determining the odds of disease development (Fig 1).

Genetic markers could possibly also have everyday clinical utility due to that the accuracy of methods predicting GDM and the identification of individuals who are at high risk of developing GDM with pre-pregnancy tests are still inadequate. The sensitivity of clinical risk factor based GDM predictions (conventional risk factors: age, BMI, ethnicity, DM family history, obstetric history—or novel approaches: circulating adiponectin) remains lower than 70% [48, 49].

A limitation of our study is that the sample size allows only the identification of the most robust genetic associations with GDM development (i.e.: OR>1.4) or related traits and did not allow to detect other genetic susceptibility factors that may have a smaller, but still significant effects on disease development or glycemic traits. These data would need confirmation a in a well-powered replication follow-up study.

Supporting Information

S1 Table. List of the 77 SNPs assessed and their reported major function and disease / pathology association.

https://doi.org/10.1371/journal.pone.0169781.s001

(PDF)

S2 Table.

Panel—A. Odds Ratios and Standardized Effect Sizes for each gene variant (SNP) assessed in the study after adjustment by age and BMI. Data are presented for the two GDM diagnostic criterion (m'99 WHO and IADPSG) systems applied in the study both under the dominant and the additive genetic models. The SNPs identified in this study with GDM as a binary trait are indicated in bold. (See also Table 2 for details). Panel—B Odds Ratios and Standardized Effect Sizes for each gene variant (SNP) assessed in the Study. Data are presented for the two GDM diagnostic criterion (m'99 WHO and IADPSG) systems applied in the study both under the dominant and the additive genetic models and adjusted by age only.

https://doi.org/10.1371/journal.pone.0169781.s002

(PDF)

S3 Table. Minor Allele Frequencies (MAF) in the case-control study populations according to the two GDM diagnostic criteria applied and in the European general population.

https://doi.org/10.1371/journal.pone.0169781.s003

(PDF)

S4 Table. Chi Squared test results for the assessment of the deviation from the Hardy-Weinberg Equilibrium (HWE) genotype distributions.

https://doi.org/10.1371/journal.pone.0169781.s004

(PDF)

S5 Table. The re-calculated mean clinical data of the Austrian and Hungarian pregnant populations.

https://doi.org/10.1371/journal.pone.0169781.s005

(PDF)

Acknowledgments

The authors thank Dr. András Zempléni and Dr. Tamás Pröhle from the Department of Probability Theory and Statistics, Eötvös Loránd University, Budapest, Hungary for their guidance, help and contribution to the statistical analysis of data. We are also grateful for Andrew Symons, Ph.D. for English language editing.

Author Contributions

Conceptualization: GF KR AS AK-W.
Data curation: GF.
Formal analysis: GF KR AS AK-W ZA OH JH ÁN.
Funding acquisition: GF KR AS AK-W.
Investigation: GF KR AS AK-W ZA OH JH DB-T ISz ÁN FK ZsK.
Methodology: GF KR AS AK-W ZsK.
Project administration: GF AK-W.
Resources: GF KR AS AK-W.
Software: LN.
Supervision: GF AS AK-W JR.
Validation: GF KR.
Visualization: GF ÁN.
Writing – original draft: GF KR JH AS AK-W.
Writing – review & editing: GF KR JH AS AK-W ZA ISz ÁN ZsK LN.

References

1. Buckley BS, Harreiter J, Damm P, Corcoy R, Chico A, Simmons D, et al. Gestational diabetes mellitus in Europe: prevalence, current screening practice and barriers to screening. A review. Diabet Med. 2012;29(7):844–54. pmid:22150506
- View Article
- PubMed/NCBI
- Google Scholar
2. Kun A., Tornoczky J., Sudar Z., Kerenyi Z., Tabak A.G.. Pregnancy outcomes of women with untreated GDM (according to the WHO 2013 diagnostic criteria). Diabetologia. 2015;58 (Suppl 1):S74.
- View Article
- Google Scholar
3. Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ, et al. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care. 2007;30(8):2070–6. pmid:17416786
- View Article
- PubMed/NCBI
- Google Scholar
4. Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care. 2007;30 Suppl 2:S141–6.
- View Article
- Google Scholar
5. Williams MA, Qiu C, Dempsey JC, Luthy DA. Familial aggregation of type 2 diabetes and chronic hypertension in women with gestational diabetes mellitus. J Reprod Med. 2003;48(12):955–62. pmid:14738023
- View Article
- PubMed/NCBI
- Google Scholar
6. Saisho Y, Miyakoshi K, Tanaka M, Shimada A, Ikenoue S, Kadohira I, et al. Beta cell dysfunction and its clinical significance in gestational diabetes. Endocr J. 2010;57(11):973–80. pmid:20847480
- View Article
- PubMed/NCBI
- Google Scholar
7. Kautzky-Willer A, Prager R, Waldhausl W, Pacini G, Thomaseth K, Wagner OF, et al. Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. Diabetes Care. 1997;20(11):1717–23. pmid:9353615
- View Article
- PubMed/NCBI
- Google Scholar
8. Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag A. Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes. 2005;54(1):275–83. pmid:15616039
- View Article
- PubMed/NCBI
- Google Scholar
9. Huopio H, Cederberg H, Vangipurapu J, Hakkarainen H, Paakkonen M, Kuulasmaa T, et al. Association of risk variants for type 2 diabetes and hyperglycemia with gestational diabetes. Eur J Endocrinol. 2013;169(3):291–7. pmid:23761423
- View Article
- PubMed/NCBI
- Google Scholar
10. Lauenborg J, Grarup N, Damm P, Borch-Johnsen K, Jorgensen T, Pedersen O, et al. Common type 2 diabetes risk gene variants associate with gestational diabetes. J Clin Endocrinol Metab. 2009;94(1):145–50. pmid:18984664
- View Article
- PubMed/NCBI
- Google Scholar
11. Kwak SH, Kim S-H, Cho YM, Go MJ, Cho YS, Choi SH, et al. A Genome-Wide Association Study of Gestational Diabetes Mellitus in Korean Women. Diabetes. 2012;61(2):531–41. pmid:22233651
- View Article
- PubMed/NCBI
- Google Scholar
12. Cho YM, Kim TH, Lim S, Choi SH, Shin HD, Lee HK, et al. Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. Diabetologia. 2009;52(2):253–61. pmid:19002430
- View Article
- PubMed/NCBI
- Google Scholar
13. Freathy RM, Hayes MG, Urbanek M, Lowe LP, Lee H, Ackerman C, et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: common genetic variants in GCK and TCF7L2 are associated with fasting and postchallenge glucose levels in pregnancy and with the new consensus definition of gestational diabetes mellitus from the International Association of Diabetes and Pregnancy Study Groups. Diabetes. 2010;59(10):2682–9. pmid:20682688
- View Article
- PubMed/NCBI
- Google Scholar
14. Liao S, Liu Y, Tan Y, Gan L, Mei J, Song W, et al. Association of genetic variants of melatonin receptor 1B with gestational plasma glucose level and risk of glucose intolerance in pregnant Chinese women. PLoS One. 2012;7(7):e40113. pmid:22768333
- View Article
- PubMed/NCBI
- Google Scholar
15. Vejrazkova D, Lukasova P, Vankova M, Vcelak J, Bradnova O, Cirmanova V, et al. MTNR1B Genetic Variability Is Associated with Gestational Diabetes in Czech Women. Int J Endocrinol. 2014;2014:508923. pmid:25132852
- View Article
- PubMed/NCBI
- Google Scholar
16. Robitaille J, Grant AM. The genetics of gestational diabetes mellitus: evidence for relationship with type 2 diabetes mellitus. Genetics in medicine: official journal of the American College of Medical Genetics. 2008;10(4):240–50.
- View Article
- Google Scholar
17. Mao H, Li Q, Gao S. Meta-analysis of the relationship between common type 2 diabetes risk gene variants with gestational diabetes mellitus. PloS one. 2012;7(9):e45882. pmid:23029294
- View Article
- PubMed/NCBI
- Google Scholar
18. Wu L, Cui L, Tam WH, Ma RC, Wang CC. Genetic variants associated with gestational diabetes mellitus: a meta-analysis and subgroup analysis. Sci Rep. 2016;6:30539. pmid:27468700
- View Article
- PubMed/NCBI
- Google Scholar
19. Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes. 2015;6(1):87–123. pmid:25774817
- View Article
- PubMed/NCBI
- Google Scholar
20. WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. WHO/NCD/NCS/992 ed.
- View Article
- Google Scholar
21. International Association of Diabetes, Pregnancy Study Groups Consensus P, Metzger BE, Gabbe SG, Persson B, Buchanan TA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676–82. pmid:20190296
- View Article
- PubMed/NCBI
- Google Scholar
22. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol. 2009;62(6):597–608 e4. pmid:19217256
- View Article
- PubMed/NCBI
- Google Scholar
23. Mikolajczyk RT, Zhang J, Betran AP, Souza JP, Mori R, Gulmezoglu AM, et al. A global reference for fetal-weight and birthweight percentiles. Lancet. 2011;377(9780):1855–61. pmid:21621717
- View Article
- PubMed/NCBI
- Google Scholar
24. Coustan DR, Lowe LP, Metzger BE, Dyer AR, International Association of D, Pregnancy Study G The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol. 2010;202(6):654 e1–6.
- View Article
- Google Scholar
25. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41(1):77–81. pmid:19060907
- View Article
- PubMed/NCBI
- Google Scholar
26. Li H, Gan W, Lu L, Dong X, Han X, Hu C, et al. A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans. Diabetes. 2013;62(1):291–8. pmid:22961080
- View Article
- PubMed/NCBI
- Google Scholar
27. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42(7):579–89. Epub 2010/06/29. pmid:20581827
- View Article
- PubMed/NCBI
- Google Scholar
28. Zheng JS, Arnett DK, Parnell LD, Smith CE, Li D, Borecki IB, et al. Modulation by dietary fat and carbohydrate of IRS1 association with type 2 diabetes traits in two populations of different ancestries. Diabetes Care. 2013;36(9):2621–7. pmid:23596181
- View Article
- PubMed/NCBI
- Google Scholar
29. Chen P, Takeuchi F, Lee JY, Li H, Wu JY, Liang J, et al. Multiple nonglycemic genomic loci are newly associated with blood level of glycated hemoglobin in East Asians. Diabetes. 2014;63(7):2551–62. pmid:24647736
- View Article
- PubMed/NCBI
- Google Scholar
30. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316(5829):1331–6. Epub 2007/04/28. pmid:17463246
- View Article
- PubMed/NCBI
- Google Scholar
31. Hara K, Fujita H, Johnson TA, Yamauchi T, Yasuda K, Horikoshi M, et al. Genome-wide association study identifies three novel loci for type 2 diabetes. Hum Mol Genet. 2014;23(1):239–46. pmid:23945395
- View Article
- PubMed/NCBI
- Google Scholar
32. Tuerxunyiming M, Mohemaiti P, Wufuer H, Tuheti A. Association of rs7754840 G/C polymorphisms in CDKAL1 with type 2 diabetes: a meta-analysis of 70141 subjects. Int J Clin Exp Med. 2015;8(10):17392–405. pmid:26770330
- View Article
- PubMed/NCBI
- Google Scholar
33. Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, et al. Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study. PLoS Genet. 2008;4(12):e1000312. pmid:19096518
- View Article
- PubMed/NCBI
- Google Scholar
34. Boesgaard TW, Zilinskaite J, Vanttinen M, Laakso M, Jansson PA, Hammarstedt A, et al. The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients—the EUGENE2 study. Diabetologia. 2008;51(5):816–20. pmid:18324385
- View Article
- PubMed/NCBI
- Google Scholar
35. Grotenfelt NE, Wasenius NS, Rono K, Laivuori H, Stach-Lempinen B, Orho-Melander M, et al. Interaction between rs10830963 polymorphism in MTNR1B and lifestyle intervention on occurrence of gestational diabetes. Diabetologia. 2016;59(8):1655–8. pmid:27209463
- View Article
- PubMed/NCBI
- Google Scholar
36. Zhang C, Bao W, Rong Y, Yang H, Bowers K, Yeung E, et al. Genetic variants and the risk of gestational diabetes mellitus: a systematic review. Human reproduction update. 2013;19(4):376–90. pmid:23690305
- View Article
- PubMed/NCBI
- Google Scholar
37. Vlassi M, Gazouli M, Paltoglou G, Christopoulos P, Florentin L, Kassi G, et al. The rs10830963 variant of melatonin receptor MTNR1B is associated with increased risk for gestational diabetes mellitus in a Greek population. Hormones (Athens). 2012;11(1):70–6.
- View Article
- Google Scholar
38. Gaulton KJ, Ferreira T, Lee Y, Raimondo A, Magi R, Reschen ME, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet. 2015;47(12):1415–25. pmid:26551672
- View Article
- PubMed/NCBI
- Google Scholar
39. Peschke E, Bahr I, Muhlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14(4):6981–7015. pmid:23535335
- View Article
- PubMed/NCBI
- Google Scholar
40. Huerta-Chagoya A, Vazquez-Cardenas P, Moreno-Macias H, Tapia-Maruri L, Rodriguez-Guillen R, Lopez-Vite E, et al. Genetic determinants for gestational diabetes mellitus and related metabolic traits in Mexican women. PLoS One. 2015;10(5):e0126408. pmid:25973943
- View Article
- PubMed/NCBI
- Google Scholar
41. Soyal SM, Felder T, Auer S, Oberkofler H, Iglseder B, Paulweber B, et al. Associations of Haplotypes Upstream of IRS1 with Insulin Resistance, Type 2 Diabetes, Dyslipidemia, Preclinical Atherosclerosis, and Skeletal Muscle LOC646736 mRNA Levels, Associations of Haplotypes Upstream of IRS1 with Insulin Resistance, Type 2 Diabetes, Dyslipidemia, Preclinical Atherosclerosis, and Skeletal Muscle LOC646736 mRNA Levels. Journal of Diabetes Research, Journal of Diabetes Research. 2015;2015, 2015:e405371.
- View Article
- Google Scholar
42. Santos IC, Frigeri HR, Rea RR, Almeida AC, Souza EM, Pedrosa FO, et al. The glucokinase gene promoter polymorphism -30G>A (rs1799884) is associated with fasting glucose in healthy pregnant women but not with gestational diabetes. Clin Chim Acta. 2010;411(11–12):892–3. pmid:20227404
- View Article
- PubMed/NCBI
- Google Scholar
43. Cho YM, Kim TH, Lim S, Choi SH, Shin HD, Lee HK, et al. Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. Diabetologia. 2008;52(2):253–61. pmid:19002430
- View Article
- PubMed/NCBI
- Google Scholar
44. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Multiple type 2 diabetes susceptibility genes following genome-wide association scan in UK samples. Science (New York, NY). 2007;316(5829):1336–41.
- View Article
- Google Scholar
45. Langenberg C, Pascoe L, Mari A, Tura A, Laakso M, Frayling TM, et al. Common genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated with decreased early-phase insulin response. Diabetologia. 2009;52(8):1537–42. pmid:19455304
- View Article
- PubMed/NCBI
- Google Scholar
46. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nature genetics. 2009;41(1):82–8. pmid:19060908
- View Article
- PubMed/NCBI
- Google Scholar
47. Groenewoud MJ, Dekker JM, Fritsche A, Reiling E, Nijpels G, Heine RJ, et al. Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia. 2008;51(9):1659–63. pmid:18618095
- View Article
- PubMed/NCBI
- Google Scholar
48. Scott DA, Loveman E, McIntyre L, Waugh N. Screening for gestational diabetes: a systematic review and economic evaluation. Health technology assessment. 2002;6(11):1–161. pmid:12433317
- View Article
- PubMed/NCBI
- Google Scholar
49. Iliodromiti S, Sassarini J, Kelsey TW, Lindsay RS, Sattar N, Nelson SM. Accuracy of circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis. Diabetologia. 2016;59(4):692–9. pmid:26768001
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Buckley BS, Harreiter J, Damm P, Corcoy R, Chico A, Simmons D, et al. Gestational diabetes mellitus in Europe: prevalence, current screening practice and barriers to screening. A review. Diabet Med. 2012;29(7):844–54. pmid:22150506
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. Kun A., Tornoczky J., Sudar Z., Kerenyi Z., Tabak A.G.. Pregnancy outcomes of women with untreated GDM (according to the WHO 2013 diagnostic criteria). Diabetologia. 2015;58 (Suppl 1):S74.
View Article
Google Scholar

[6] View Article

[7] Google Scholar

[ref3] 3. Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ, et al. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care. 2007;30(8):2070–6. pmid:17416786
View Article
PubMed/NCBI
Google Scholar

[9] View Article

[10] PubMed/NCBI

[11] Google Scholar

[ref4] 4. Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care. 2007;30 Suppl 2:S141–6.
View Article
Google Scholar

[13] View Article

[14] Google Scholar

[ref5] 5. Williams MA, Qiu C, Dempsey JC, Luthy DA. Familial aggregation of type 2 diabetes and chronic hypertension in women with gestational diabetes mellitus. J Reprod Med. 2003;48(12):955–62. pmid:14738023
View Article
PubMed/NCBI
Google Scholar

[16] View Article

[17] PubMed/NCBI

[18] Google Scholar

[ref6] 6. Saisho Y, Miyakoshi K, Tanaka M, Shimada A, Ikenoue S, Kadohira I, et al. Beta cell dysfunction and its clinical significance in gestational diabetes. Endocr J. 2010;57(11):973–80. pmid:20847480
View Article
PubMed/NCBI
Google Scholar

[20] View Article

[21] PubMed/NCBI

[22] Google Scholar

[ref7] 7. Kautzky-Willer A, Prager R, Waldhausl W, Pacini G, Thomaseth K, Wagner OF, et al. Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. Diabetes Care. 1997;20(11):1717–23. pmid:9353615
View Article
PubMed/NCBI
Google Scholar

[24] View Article

[25] PubMed/NCBI

[26] Google Scholar

[ref8] 8. Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag A. Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes. 2005;54(1):275–83. pmid:15616039
View Article
PubMed/NCBI
Google Scholar

[28] View Article

[29] PubMed/NCBI

[30] Google Scholar

[ref9] 9. Huopio H, Cederberg H, Vangipurapu J, Hakkarainen H, Paakkonen M, Kuulasmaa T, et al. Association of risk variants for type 2 diabetes and hyperglycemia with gestational diabetes. Eur J Endocrinol. 2013;169(3):291–7. pmid:23761423
View Article
PubMed/NCBI
Google Scholar

[32] View Article

[33] PubMed/NCBI

[34] Google Scholar

[ref10] 10. Lauenborg J, Grarup N, Damm P, Borch-Johnsen K, Jorgensen T, Pedersen O, et al. Common type 2 diabetes risk gene variants associate with gestational diabetes. J Clin Endocrinol Metab. 2009;94(1):145–50. pmid:18984664
View Article
PubMed/NCBI
Google Scholar

[36] View Article

[37] PubMed/NCBI

[38] Google Scholar

[ref11] 11. Kwak SH, Kim S-H, Cho YM, Go MJ, Cho YS, Choi SH, et al. A Genome-Wide Association Study of Gestational Diabetes Mellitus in Korean Women. Diabetes. 2012;61(2):531–41. pmid:22233651
View Article
PubMed/NCBI
Google Scholar

[40] View Article

[41] PubMed/NCBI

[42] Google Scholar

[ref12] 12. Cho YM, Kim TH, Lim S, Choi SH, Shin HD, Lee HK, et al. Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. Diabetologia. 2009;52(2):253–61. pmid:19002430
View Article
PubMed/NCBI
Google Scholar

[44] View Article

[45] PubMed/NCBI

[46] Google Scholar

[ref13] 13. Freathy RM, Hayes MG, Urbanek M, Lowe LP, Lee H, Ackerman C, et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: common genetic variants in GCK and TCF7L2 are associated with fasting and postchallenge glucose levels in pregnancy and with the new consensus definition of gestational diabetes mellitus from the International Association of Diabetes and Pregnancy Study Groups. Diabetes. 2010;59(10):2682–9. pmid:20682688
View Article
PubMed/NCBI
Google Scholar

[48] View Article

[49] PubMed/NCBI

[50] Google Scholar

[ref14] 14. Liao S, Liu Y, Tan Y, Gan L, Mei J, Song W, et al. Association of genetic variants of melatonin receptor 1B with gestational plasma glucose level and risk of glucose intolerance in pregnant Chinese women. PLoS One. 2012;7(7):e40113. pmid:22768333
View Article
PubMed/NCBI
Google Scholar

[52] View Article

[53] PubMed/NCBI

[54] Google Scholar

[ref15] 15. Vejrazkova D, Lukasova P, Vankova M, Vcelak J, Bradnova O, Cirmanova V, et al. MTNR1B Genetic Variability Is Associated with Gestational Diabetes in Czech Women. Int J Endocrinol. 2014;2014:508923. pmid:25132852
View Article
PubMed/NCBI
Google Scholar

[56] View Article

[57] PubMed/NCBI

[58] Google Scholar

[ref16] 16. Robitaille J, Grant AM. The genetics of gestational diabetes mellitus: evidence for relationship with type 2 diabetes mellitus. Genetics in medicine: official journal of the American College of Medical Genetics. 2008;10(4):240–50.
View Article
Google Scholar

[60] View Article

[61] Google Scholar

[ref17] 17. Mao H, Li Q, Gao S. Meta-analysis of the relationship between common type 2 diabetes risk gene variants with gestational diabetes mellitus. PloS one. 2012;7(9):e45882. pmid:23029294
View Article
PubMed/NCBI
Google Scholar

[63] View Article

[64] PubMed/NCBI

[65] Google Scholar

[ref18] 18. Wu L, Cui L, Tam WH, Ma RC, Wang CC. Genetic variants associated with gestational diabetes mellitus: a meta-analysis and subgroup analysis. Sci Rep. 2016;6:30539. pmid:27468700
View Article
PubMed/NCBI
Google Scholar

[67] View Article

[68] PubMed/NCBI

[69] Google Scholar

[ref19] 19. Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes. 2015;6(1):87–123. pmid:25774817
View Article
PubMed/NCBI
Google Scholar

[71] View Article

[72] PubMed/NCBI

[73] Google Scholar

[ref20] 20. WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. WHO/NCD/NCS/992 ed.
View Article
Google Scholar

[75] View Article

[76] Google Scholar

[ref21] 21. International Association of Diabetes, Pregnancy Study Groups Consensus P, Metzger BE, Gabbe SG, Persson B, Buchanan TA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676–82. pmid:20190296
View Article
PubMed/NCBI
Google Scholar

[78] View Article

[79] PubMed/NCBI

[80] Google Scholar

[ref22] 22. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol. 2009;62(6):597–608 e4. pmid:19217256
View Article
PubMed/NCBI
Google Scholar

[82] View Article

[83] PubMed/NCBI

[84] Google Scholar

[ref23] 23. Mikolajczyk RT, Zhang J, Betran AP, Souza JP, Mori R, Gulmezoglu AM, et al. A global reference for fetal-weight and birthweight percentiles. Lancet. 2011;377(9780):1855–61. pmid:21621717
View Article
PubMed/NCBI
Google Scholar

[86] View Article

[87] PubMed/NCBI

[88] Google Scholar

[ref24] 24. Coustan DR, Lowe LP, Metzger BE, Dyer AR, International Association of D, Pregnancy Study G The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol. 2010;202(6):654 e1–6.
View Article
Google Scholar

[90] View Article

[91] Google Scholar

[ref25] 25. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41(1):77–81. pmid:19060907
View Article
PubMed/NCBI
Google Scholar

[93] View Article

[94] PubMed/NCBI

[95] Google Scholar

[ref26] 26. Li H, Gan W, Lu L, Dong X, Han X, Hu C, et al. A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans. Diabetes. 2013;62(1):291–8. pmid:22961080
View Article
PubMed/NCBI
Google Scholar

[97] View Article

[98] PubMed/NCBI

[99] Google Scholar

[ref27] 27. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42(7):579–89. Epub 2010/06/29. pmid:20581827
View Article
PubMed/NCBI
Google Scholar

[101] View Article

[102] PubMed/NCBI

[103] Google Scholar

[ref28] 28. Zheng JS, Arnett DK, Parnell LD, Smith CE, Li D, Borecki IB, et al. Modulation by dietary fat and carbohydrate of IRS1 association with type 2 diabetes traits in two populations of different ancestries. Diabetes Care. 2013;36(9):2621–7. pmid:23596181
View Article
PubMed/NCBI
Google Scholar

[105] View Article

[106] PubMed/NCBI

[107] Google Scholar

[ref29] 29. Chen P, Takeuchi F, Lee JY, Li H, Wu JY, Liang J, et al. Multiple nonglycemic genomic loci are newly associated with blood level of glycated hemoglobin in East Asians. Diabetes. 2014;63(7):2551–62. pmid:24647736
View Article
PubMed/NCBI
Google Scholar

[109] View Article

[110] PubMed/NCBI

[111] Google Scholar

[ref30] 30. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316(5829):1331–6. Epub 2007/04/28. pmid:17463246
View Article
PubMed/NCBI
Google Scholar

[113] View Article

[114] PubMed/NCBI

[115] Google Scholar

[ref31] 31. Hara K, Fujita H, Johnson TA, Yamauchi T, Yasuda K, Horikoshi M, et al. Genome-wide association study identifies three novel loci for type 2 diabetes. Hum Mol Genet. 2014;23(1):239–46. pmid:23945395
View Article
PubMed/NCBI
Google Scholar

[117] View Article

[118] PubMed/NCBI

[119] Google Scholar

[ref32] 32. Tuerxunyiming M, Mohemaiti P, Wufuer H, Tuheti A. Association of rs7754840 G/C polymorphisms in CDKAL1 with type 2 diabetes: a meta-analysis of 70141 subjects. Int J Clin Exp Med. 2015;8(10):17392–405. pmid:26770330
View Article
PubMed/NCBI
Google Scholar

[121] View Article

[122] PubMed/NCBI

[123] Google Scholar

[ref33] 33. Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, et al. Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study. PLoS Genet. 2008;4(12):e1000312. pmid:19096518
View Article
PubMed/NCBI
Google Scholar

[125] View Article

[126] PubMed/NCBI

[127] Google Scholar

[ref34] 34. Boesgaard TW, Zilinskaite J, Vanttinen M, Laakso M, Jansson PA, Hammarstedt A, et al. The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients—the EUGENE2 study. Diabetologia. 2008;51(5):816–20. pmid:18324385
View Article
PubMed/NCBI
Google Scholar

[129] View Article

[130] PubMed/NCBI

[131] Google Scholar

[ref35] 35. Grotenfelt NE, Wasenius NS, Rono K, Laivuori H, Stach-Lempinen B, Orho-Melander M, et al. Interaction between rs10830963 polymorphism in MTNR1B and lifestyle intervention on occurrence of gestational diabetes. Diabetologia. 2016;59(8):1655–8. pmid:27209463
View Article
PubMed/NCBI
Google Scholar

[133] View Article

[134] PubMed/NCBI

[135] Google Scholar

[ref36] 36. Zhang C, Bao W, Rong Y, Yang H, Bowers K, Yeung E, et al. Genetic variants and the risk of gestational diabetes mellitus: a systematic review. Human reproduction update. 2013;19(4):376–90. pmid:23690305
View Article
PubMed/NCBI
Google Scholar

[137] View Article

[138] PubMed/NCBI

[139] Google Scholar

[ref37] 37. Vlassi M, Gazouli M, Paltoglou G, Christopoulos P, Florentin L, Kassi G, et al. The rs10830963 variant of melatonin receptor MTNR1B is associated with increased risk for gestational diabetes mellitus in a Greek population. Hormones (Athens). 2012;11(1):70–6.
View Article
Google Scholar

[141] View Article

[142] Google Scholar

[ref38] 38. Gaulton KJ, Ferreira T, Lee Y, Raimondo A, Magi R, Reschen ME, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet. 2015;47(12):1415–25. pmid:26551672
View Article
PubMed/NCBI
Google Scholar

[144] View Article

[145] PubMed/NCBI

[146] Google Scholar

[ref39] 39. Peschke E, Bahr I, Muhlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14(4):6981–7015. pmid:23535335
View Article
PubMed/NCBI
Google Scholar

[148] View Article

[149] PubMed/NCBI

[150] Google Scholar

[ref40] 40. Huerta-Chagoya A, Vazquez-Cardenas P, Moreno-Macias H, Tapia-Maruri L, Rodriguez-Guillen R, Lopez-Vite E, et al. Genetic determinants for gestational diabetes mellitus and related metabolic traits in Mexican women. PLoS One. 2015;10(5):e0126408. pmid:25973943
View Article
PubMed/NCBI
Google Scholar

[152] View Article

[153] PubMed/NCBI

[154] Google Scholar

[ref41] 41. Soyal SM, Felder T, Auer S, Oberkofler H, Iglseder B, Paulweber B, et al. Associations of Haplotypes Upstream of IRS1 with Insulin Resistance, Type 2 Diabetes, Dyslipidemia, Preclinical Atherosclerosis, and Skeletal Muscle LOC646736 mRNA Levels, Associations of Haplotypes Upstream of IRS1 with Insulin Resistance, Type 2 Diabetes, Dyslipidemia, Preclinical Atherosclerosis, and Skeletal Muscle LOC646736 mRNA Levels. Journal of Diabetes Research, Journal of Diabetes Research. 2015;2015, 2015:e405371.
View Article
Google Scholar

[156] View Article

[157] Google Scholar

[ref42] 42. Santos IC, Frigeri HR, Rea RR, Almeida AC, Souza EM, Pedrosa FO, et al. The glucokinase gene promoter polymorphism -30G>A (rs1799884) is associated with fasting glucose in healthy pregnant women but not with gestational diabetes. Clin Chim Acta. 2010;411(11–12):892–3. pmid:20227404
View Article
PubMed/NCBI
Google Scholar

[159] View Article

[160] PubMed/NCBI

[161] Google Scholar

[ref43] 43. Cho YM, Kim TH, Lim S, Choi SH, Shin HD, Lee HK, et al. Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. Diabetologia. 2008;52(2):253–61. pmid:19002430
View Article
PubMed/NCBI
Google Scholar

[163] View Article

[164] PubMed/NCBI

[165] Google Scholar

[ref44] 44. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Multiple type 2 diabetes susceptibility genes following genome-wide association scan in UK samples. Science (New York, NY). 2007;316(5829):1336–41.
View Article
Google Scholar

[167] View Article

[168] Google Scholar

[ref45] 45. Langenberg C, Pascoe L, Mari A, Tura A, Laakso M, Frayling TM, et al. Common genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated with decreased early-phase insulin response. Diabetologia. 2009;52(8):1537–42. pmid:19455304
View Article
PubMed/NCBI
Google Scholar

[170] View Article

[171] PubMed/NCBI

[172] Google Scholar

[ref46] 46. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nature genetics. 2009;41(1):82–8. pmid:19060908
View Article
PubMed/NCBI
Google Scholar

[174] View Article

[175] PubMed/NCBI

[176] Google Scholar

[ref47] 47. Groenewoud MJ, Dekker JM, Fritsche A, Reiling E, Nijpels G, Heine RJ, et al. Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia. 2008;51(9):1659–63. pmid:18618095
View Article
PubMed/NCBI
Google Scholar

[178] View Article

[179] PubMed/NCBI

[180] Google Scholar

[ref48] 48. Scott DA, Loveman E, McIntyre L, Waugh N. Screening for gestational diabetes: a systematic review and economic evaluation. Health technology assessment. 2002;6(11):1–161. pmid:12433317
View Article
PubMed/NCBI
Google Scholar

[182] View Article

[183] PubMed/NCBI

[184] Google Scholar

[ref49] 49. Iliodromiti S, Sassarini J, Kelsey TW, Lindsay RS, Sattar N, Nelson SM. Accuracy of circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis. Diabetologia. 2016;59(4):692–9. pmid:26768001
View Article
PubMed/NCBI
Google Scholar

[186] View Article

[187] PubMed/NCBI

[188] Google Scholar

Figures

Abstract

Context

Objective

Methods

Results

Conclusions

Introduction

Materials and Methods

Patients

Inclusion criteria

Exclusion criteria

Clinical data collection

Research design

Genomic DNA isolation and genotyping

Statistical analysis

GDM as binary trait.

Glycemic traits.

Clinical characteristics.

Results

GDM as binary trait

Association of MTNR1B rs10830963 with GDM.

CDKAL1 rs7754840 and GCK rs799884 risk polymorphisms in GDM.

Protective polymorphisms, including a novel association signal with GDM.

Association between MTNR1B, GCK, TCF7L2, SLC30A8, LOC646736/IRS1 gene variants and glycemic traits

Fasting plasma glucose levels.

Two hour plasma glucose levels at OGTT.

Pre-pregnancy body mass index

Discussion

Supporting Information

S1 Table. List of the 77 SNPs assessed and their reported major function and disease / pathology association.

S2 Table.

S3 Table. Minor Allele Frequencies (MAF) in the case-control study populations according to the two GDM diagnostic criteria applied and in the European general population.

S4 Table. Chi Squared test results for the assessment of the deviation from the Hardy-Weinberg Equilibrium (HWE) genotype distributions.

S5 Table. The re-calculated mean clinical data of the Austrian and Hungarian pregnant populations.

Acknowledgments

Author Contributions

References